Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 49 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaActive, not recruitingNCT05732805Phase 3
• Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)Status unknownNCT05732493Phase 2
• Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid TumorsActive, not recruitingNCT05731752Phase 1
• Cemiplimab/Peg-Interferon-α in Advanced CSCCWithdrawnNCT05729139Phase 1
• Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast CancerStatus unknownNCT05726175Phase 2
• Domvanalimab and Zimberelimab in Advanced Liver CancersActive, not recruitingNCT05724563Phase 2
• CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPCStatus unknownNCT05724355Phase 2
• A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal CancerActive, not recruitingNCT05723562Phase 2
• Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin LymphomaActive, not recruitingNCT05723055Phase 2
• Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic CancerCompletedNCT05721846Phase 1
• Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT05721755Phase 3
• Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid TumorsTerminatedNCT05718219Phase 1
• Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the LungWithdrawnNCT05717140Phase 1
• Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaActive, not recruitingNCT05715931Phase 2
• Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical SurgeryActive, not recruitingNCT05713838Phase 2
• A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin LymphomaWithdrawnNCT05711628Phase 3
• IMM60 and Pembrolizumab in Melanoma and NSCLCTerminatedNCT05709821Phase 1/2
• A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)CompletedNCT05708950Phase 1/2
• Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant TumorsActive, not recruitingNCT05707910Phase 1
• Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain MetastasesCompletedNCT05704933Early Phase 1
• A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.Active, not recruitingNCT05704634Phase 1
• SIRT With Tremelimumab and Durvalumab for Resectable HCCActive, not recruitingNCT05701488Phase 1
• Neoadjuvant Chemoimmunotherapy in Recurrent GlioblastomaStatus unknownNCT05700955Phase 1
• Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic CholangiocarcinomaStatus unknownNCT05697237Not applicable
• Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)Active, not recruitingNCT05696548Phase 2
• XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor TherapyTerminatedNCT05695898Phase 1
• Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated LiposarcomaActive, not recruitingNCT05694871Phase 2
• A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung CancerActive, not recruitingNCT05690945Phase 3
• Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal CancerWithdrawnNCT05690035Phase 2
• Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung AdenocarcinomaActive, not recruitingNCT05689671Phase 4
• Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder CancerWithdrawnNCT05687721Phase 1/2
• Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsActive, not recruitingNCT05687266Phase 3
• MEDI5752 in Japanese Patients With Advanced Solid Tumors.CompletedNCT05685472Phase 1
• DUMAS: Neo-Adjuvant Immunotherapy for Pancoast TumorsActive, not recruitingNCT05684276Phase 2
• A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal CancerStatus unknownNCT05684211Phase 2
• ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPCActive, not recruitingNCT05682443Phase 1/2
• A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast CancerStatus unknownNCT05681728Phase 2
• Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).Active, not recruitingNCT05681039Phase 2
• Study With Various Immunotherapy Treatments in Participants With Lung CancerActive, not recruitingNCT05676931Phase 2
• A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)Active, not recruitingNCT05675579Phase 2
• Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung AdenocarcinomaStatus unknownNCT05675033Phase 2
• Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC PatientsCompletedNCT05673577Phase 2
• Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast CancerSuspendedNCT05673200Phase 1
• Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior ChemotherapyActive, not recruitingNCT05672316Phase 1/2
• Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's TransformationActive, not recruitingNCT05672173Phase 2
• ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsActive, not recruitingNCT05671510Phase 3
• CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain MetastasesSuspendedNCT05669352Phase 1/2
• A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT05668858Phase 1/2
• Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic TherapyCompletedNCT05665348Phase 2/3
• JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung CancerCompletedNCT05664971Phase 1/2
• Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCSuspendedNCT05663710Phase 1/2
• Response to Immunotherapy in MMR-deficient Localized Colon CancerCompletedNCT05662527Phase 2
• A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.Active, not recruitingNCT05661955Phase 1/2
• Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin LymphomaStatus unknownNCT05660993Phase 2
• Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes AlterationsActive, not recruitingNCT05659914Phase 2
• Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast CancerSuspendedNCT05656131Phase 2
• A Study of AK130 in Patients With Advanced Malignant TumorsCompletedNCT05653284Phase 1
• IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract CancerStatus unknownNCT05653180Phase 1/2
• A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal CancerActive, not recruitingNCT05652894Phase 3
• A Phase I Study of QL1604 in Subjects With Advanced Solid TumorsStatus unknownNCT05649761Phase 1
• A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerActive, not recruitingNCT05645692Phase 2
• Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid TumorsStatus unknownNCT05645315Phase 1/2
• A Study of AK129 in Patients With Advanced Malignant TumorsCompletedNCT05645276Phase 1
• Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese ParticipantsWithdrawnNCT05644626Phase 1
• A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular CarcinomaActive, not recruitingNCT05644379Phase 1
• Study of AK119 and AK112 With or Without Chemotherapy for NSCLC PatientsTerminatedNCT05636267Phase 1/2
• Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic CancerStatus unknownNCT05634564Phase 2
• Study of Novel Treatment Combinations in Patients With Lung CancerActive, not recruitingNCT05633667Phase 2
• Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyActive, not recruitingNCT05633602Phase 3
• ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.Active, not recruitingNCT05632939Phase 1/2
• AGEN1423 and Botensilimab w/ or w/o Chemo in PDACActive, not recruitingNCT05632328Phase 2
• CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid TumorsActive, not recruitingNCT05631899Phase 1
• A Study of Botensilimab in Participants With Metastatic Pancreatic CancerCompletedNCT05630183Phase 2
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)Active, not recruitingNCT05629585Phase 3
• A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHLActive, not recruitingNCT05627856Phase 1/2
• FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal CancerActive, not recruitingNCT05627635Phase 1/2
• Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard ChemotherapyStatus unknownNCT05627427Phase 2
• Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric CancerStatus unknownNCT05627414Phase 2
• Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction AdenocarcinomaActive, not recruitingNCT05625737Phase 2
• Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver FunctionsCompletedNCT05622071Phase 2
• HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular CarcinomaActive, not recruitingNCT05621499Not applicable
• Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the ThoraxActive, not recruitingNCT05617963Phase 2
• Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular CarcinomaStatus unknownNCT05617430Phase 2
• Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.Active, not recruitingNCT05615142Phase 1
• Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based ChemotherapyWithdrawnNCT05614453Phase 2
• A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid TumorsActive, not recruitingNCT05614102Phase 1
• Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma PatientsStatus unknownNCT05611463Phase 2
• Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)Active, not recruitingNCT05609968Phase 3
• Electroporation and Immunotherapy in Metastatic Colorectal CancerTerminatedNCT05609656Phase 2
• Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationActive, not recruitingNCT05609578Phase 2
• Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different GenotypesStatus unknownNCT05608785Phase 1/2
• A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryActive, not recruitingNCT05608291Phase 3
• A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerActive, not recruitingNCT05608044Phase 2
• A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced TumoursStatus unknownNCT05607563Phase 1
• Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)Status unknownNCT05603065Phase 4
• A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT05603039Phase 1/2
• Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)Status unknownNCT05603013Phase 2
• Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm StudyActive, not recruitingNCT05602935Phase 2
• A Phase 1 Study of ADA-011 for Subjects With Advanced Solid TumorsTerminatedNCT05601219Phase 1
• A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell CarcinomaStatus unknownNCT05600998Not applicable

← Immune Checkpoint Inhibitors overview